WOBURN, Mass. , July 11, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expansion of its sales force to drive further adoption of Quell ® Fibromyalgia, which is the first and only medical device authorized by the U.S. Food and Drug Administration (FDA) to help reduce the

WOBURN, Mass. , July 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market on July 27, 2023 . The Company will host a conference call at 8:00 a.m., Eastern Time on July 27,

WOBURN, Mass. , July 27, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes through

WOBURN, Mass. , Aug. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on September 6, 2023 . This live, interactive, online event will give shareholders and the investment community the opportunity to interact in

WOBURN, Mass. , Sept. 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on October 4, 2023 . This live, interactive, online event will give shareholders and the investment community the opportunity to interact in

WOBURN, Mass. , Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA). As a Proud Sponsor NeuroMetrix will support the NFA’s mission to provide education, support, and advocacy for

WOBURN, Mass. , Oct. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q3 2023 business and financial highlights before the opening of the market on October 26, 2023 . The Company will host a conference call at 8:00 a.m., Eastern Time on

WOBURN, Mass. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes through

WOBURN, Mass. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on Wednesday, November 1, 2023 . This live, interactive, online event will give shareholders and the investment community the opportunity to

WOBURN, Mass. , Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ: NURO) today announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on November 21, 2023 (the “Effective Time”). The shares underlying the Company's outstanding options will